CAT Gains Access to Incyte s Database, Secures Rights to Develop Products | GenomeWeb

NEW YORK, Dec. 19 – Cambridge Antibody Technology of Melbourn, UK, has licensed access to Incyte’s LifeSeq Gold database and obtained options for the rights to develop products based on the data, the companies said Wednesday.

CAT will use the data as well as cDNA clones Incyte provides to develop antibody therapeutic products. CAT also has the right to gain the exclusive licences from Incyte develop treatments aimed at protein targets in Incyte’s database.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.